Shakeri-Nejad K - Search Results

1

AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.

Feuerbach D, Pezous N, Weiss M, Shakeri-Nejad K, Lingenhoehl K, Hoyer D, Hurth K, Bilbe G, Pryce CR, McAllister K, Chaperon F, Kucher K, Johns D, Blaettler T, Lopez Lopez C. Feuerbach D, et al. Br J Pharmacol. 2015 Mar;172(5):1292-304. doi: 10.1111/bph.13001. Epub 2015 Jan 12. Br J Pharmacol. 2015. PMID: 25363835 Free PMC article. Clinical Trial.

2

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.

Shakeri-Nejad K, Aslanis V, Veldandi UK, Mooney L, Pezous N, Brendani B, Juan A, Allison M, Perry R, Legangneux E. Shakeri-Nejad K, et al. Clin Ther. 2015 Nov 1;37(11):2489-2505.e2. doi: 10.1016/j.clinthera.2015.09.006. Epub 2015 Oct 27. Clin Ther. 2015. PMID: 26519230 Clinical Trial.

3

Cardiac Effects of Siponimod (BAF312) Re-initiation After Variable Periods of Drug Discontinuation in Healthy Subjects.

Legangneux E, Shakeri-Nejad K, Aslanis V, Sagkriotis A, Pezous N, Brendani B, Behrje R, Gutierrez M. Legangneux E, et al. Clin Ther. 2016 Mar;38(3):631-45.e1. doi: 10.1016/j.clinthera.2016.01.021. Epub 2016 Feb 23. Clin Ther. 2016. PMID: 26916566 Clinical Trial.

4

Tolerability and pharmacokinetics of ACT-280778, a novel nondihydropyridine dual L/T-type calcium channel blocker: early clinical studies in healthy male subjects using adaptive designs.

Mueller MS, Shakeri-Nejad K, Gutierrez MM, Krause A, Täubel J, Sanderson B, Dingemanse J. Mueller MS, et al. J Cardiovasc Pharmacol. 2014 Feb;63(2):120-31. doi: 10.1097/FJC.0000000000000030. J Cardiovasc Pharmacol. 2014. PMID: 24126567 Clinical Trial.

5

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.

Gardin A, Gray C, Neelakantham S, Huth F, Davidson AM, Dumitras S, Legangneux E, Shakeri-Nejad K. Gardin A, et al. Among authors: shakeri nejad k. Eur J Clin Pharmacol. 2018 Dec;74(12):1593-1604. doi: 10.1007/s00228-018-2533-2. Epub 2018 Aug 13. Eur J Clin Pharmacol. 2018. PMID: 30105453

6

Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.

Gardin A, Shakeri-Nejad K, Feller A, Huth F, Neelakantham S, Dumitras S. Gardin A, et al. Among authors: shakeri nejad k. Eur J Clin Pharmacol. 2019 Nov;75(11):1565-1574. doi: 10.1007/s00228-019-02729-7. Epub 2019 Aug 7. Eur J Clin Pharmacol. 2019. PMID: 31392364 Clinical Trial.

7

Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.

Sangana R, Xu Y, Shah B, Tian X, Zack J, Shakeri-Nejad K, Kalluri S, Jones I, Ligueros-Saylan M, Taylor AF, Jain DK, Scosyrev E, Uddin A, Laurent N, Paganoni P. Sangana R, et al. Among authors: shakeri nejad k. Clin Pharmacol Drug Dev. 2024 Jun;13(6):611-620. doi: 10.1002/cpdd.1373. Epub 2024 Feb 22. Clin Pharmacol Drug Dev. 2024. PMID: 38389387 Clinical Trial.

8

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.

Gardin A, Ufer M, Legangneux E, Rossato G, Jin Y, Su Z, Pal P, Li W, Shakeri-Nejad K. Gardin A, et al. Among authors: shakeri nejad k. Clin Pharmacokinet. 2019 Mar;58(3):349-361. doi: 10.1007/s40262-018-0700-3. Clin Pharmacokinet. 2019. PMID: 30088221 Free PMC article. Clinical Trial.

9

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects.

Shakeri-Nejad K, Gardin A, Gray C, Neelakantham S, Dumitras S, Legangneux E. Shakeri-Nejad K, et al. Clin Ther. 2020 Jan;42(1):175-195. doi: 10.1016/j.clinthera.2019.11.014. Epub 2020 Jan 8. Clin Ther. 2020. PMID: 31926605 Free article. Clinical Trial.

10

Effects of triclabendazole and its metabolite exposure on the heart-rate-corrected QT intervals: A randomized, placebo- and positive-controlled thorough QT study in healthy individuals.

Prince WT, Venishetty VK, Lecot J, Shakeri-Nejad K, Gray C, Taylor A, Iyer GR, Zack J. Prince WT, et al. Among authors: shakeri nejad k. Clin Transl Sci. 2023 Oct;16(10):1758-1767. doi: 10.1111/cts.13564. Epub 2023 Sep 8. Clin Transl Sci. 2023. PMID: 37688315 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters